Prime Editing Hits a First: DNA Rewritten Inside a Human

Prime editing just crossed a line that gene-editing researchers have been circling for years: it has been used to rewrite DNA inside a living person. According to Nature, it is the first known instance of that kind of treatment, and it happened in a clinical trial for a rare liver condition called Wilson disease.

The company behind it, Prime Medicine of Cambridge, Massachusetts, announced that it had dosed the first participant earlier this month. Results are not coming tomorrow, though. The company expects to share the first data from the study next year, so for now this is a milestone of "it was done," not "it worked."

What actually happened

Prime editing is a more precise cousin of the CRISPR-Cas9 tool that most people have heard of. Instead of cutting both strands of DNA, it can insert, delete and rewrite short stretches of genetic code. Think of it less like scissors and more like a find-and-replace function for a very long document.

In this trial, the target is the liver. Prime editing is meant to rewrite DNA in liver cells and erase a mutation that stops them from clearing out excess copper. That is a big deal because the edit happens in the body itself, rather than in cells pulled out, edited in a lab and put back.

Nature notes that Prime Medicine earlier used the technique on two people with a rare immune disorder, but that work edited blood stem cells outside the body and then injected them back in. This new trial skips the lab step entirely.

Why Wilson disease is the test case

Wilson disease is caused by mutations in a gene called ATP7B, which makes a protein that moves excess copper out of the liver. Left untreated, copper builds up and can cause liver damage, nerve damage and neurological problems.

Right now, patients rely on a complicated regimen of copper-clearing molecules and other medicines. A one-time fix is the dream. Rhonda Rowland, president of the Wilson Disease Association in Atlanta, told Nature that she never dreamed she would see this applied to her rare disease in her lifetime, and she called it going to be a really exciting year.

The Wilson Disease Association also lists the study on its participation page, noting that people who enroll receive the therapy, called PM577a, as a one-time infusion. The same page says the therapy is designed to address the genetic cause of the disease.

Why not use older gene editing tools?

Per Nature, the only gene-editing therapy the US Food and Drug Administration has approved so far is Casgevy, which treats two inherited blood disorders. It relies on CRISPR-Cas9, a tool often used to switch genes off rather than rewrite them.

Base editing, another approach, can change individual DNA letters, but it cannot make the particular corrections needed for the most common ATP7B mutations. That left prime editing, a more complex and flexible system, as the best fit for this disease.

Nature adds that no gene-editing therapy has been approved for use inside the body yet. The FDA is expected to decide early next year on an in-body CRISPR-Cas9 therapy for hereditary angioedema, a condition that causes severe swelling, so the field is about to get a real regulatory test.

The catch: risk and the long wait

Editing inside the body is attractive because making and delivering the treatment could be cheaper and faster than building a custom therapy from each person's own cells. But it comes with trade-offs. Krishanu Saha, a biomedical engineer at the University of Wisconsin-Madison, told Nature that it depends on what types of risks you are willing to accept.

Early trials like this are designed mainly to test safety and tolerability at ascending doses, and to see whether copper handling improves. One patient dosed is a starting gun, not a finish line. Any claim of a cure would be premature until the data arrives and the effect proves durable.

Why it matters for your feed

If prime editing works safely in the liver, the same approach could be pointed at other genetic diseases. Prime Medicine has said its in-body work focuses on large genetic liver diseases, which tells you where the first wave of treatments may land. You can follow more breakthroughs on our science page.

For now, the headline is simple: a technology that started as a lab idea has reached a human body. The next chapter, a year of careful safety and efficacy data, will decide whether this is the start of a new class of medicine or a very promising first step.